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Individualised cellular models of disease are a key tool for precision medicine to
recapitulate chronic inflammatory processes. Organoid models can be derived from
induced pluripotent stem cells (iPSCs) or from primary stem cells ex vivo. These models
have been emerging over the past decade and have been used to reconstruct the
respective organ-specific physiology and pathology, at an unsurpassed depth. In cancer
research, patient-derived cancer organoids opened new perspectives in predicting
therapy response and provided novel insights into tumour biology. In precision
medicine of chronic inflammatory disorders, stem-cell based organoid models are
currently being evaluated in pre-clinical pharmacodynamic studies (clinical studies in a
dish) and are employed in clinical studies, e.g., by re-transplanting autologous epithelial
organoids to re-establish intestinal barrier integrity. A particularly exciting feature of iPSC
systems is their ability to provide insights into organ systems and inflammatory disease
processes, which cannot be monitored with clinical biopsies, such as immune reactions in
neurodegenerative disorders. Refinement of differentiation protocols, and next-generation
co-culturing methods, aimed at generating self-organised, complex tissues in vitro, will be
the next logical steps. In this mini-review, we critically discuss the current state-of-the-art
stem cell and organoid technologies, as well as their future impact, potential and promises
in combating immune-mediated chronic diseases.
Keywords: stem cell, cancer, precision medicine, co-culture, host-microbe, immune-epithelial interactions,
induced pluripotent stem cells, patient derived organoidsSTEM CELLS AND ORGANOIDS – THE RISE OF NOVEL MODEL
SYSTEMS
Chronic inflammatory diseases are characterised by either a persisting stimulus for inflammatory signals
and/or an inadequate resolution of a response to tissue insults, leading to the development of cancer,
neurodegenerative or autoinflammatory disorders. In this complex, disharmonised multi-cellular
immune response, the epithelium, immune cells and the microbiome play central roles and thus the
development of adequate in vitromodels of disease, reflecting the complexity of immune interactions in
chronic inflammation, is an urgent need in all biomedical fields. However, tissue biology is veryorg December 2020 | Volume 11 | Article 5735621
Tran et al. Stem Cells and Organoid Technologychallenging to study inmammals, and progress can be hindered by
sample accessibility and ethical concerns in humans. One of the
cardinal concepts underlying organoid technology is the idea that
stem cells have the intrinsic ability to self-organise into 3D
structures that resemble in vivo organs. A major breakthrough
was achieved in 2009, when adult tissue-resident stem cells were
found to proliferate and self-organise, in vitro, into organoids (1, 2)
(Figure 1A). The method has since been adapted to generate
murine and human organoids from epithelial tissues of major
organs like skin, kidney, liver and intestine (3–6) (Figure 1B),
and used for various physiological and disease-related studies, e.g.
for complexdisorders like inflammatoryboweldisease (IBD).Using
intestinal organoids, the functional link between the IBD risk gene
ATG16L1, interleukin(IL)-22 signalling and STING-dependentFrontiers in Immunology | www.frontiersin.org 2type-I-interferon (IFN-I) response was discovered (7). Similarly,
the role of the DNA damage repair gene RNASEH2B in intestinal
inflammation and tissue regeneration was identified in organoid
models (8). Purified intestinal epithelium from inflamed intestinal
tissue obtained from IBD patients displayed distinct epigenetic and
transcriptional alternations, which were retained in organoid
cultures and correlated with disease outcome (9). Inflamed IBD
tissue-derived organoids display increased activation of typical
molecular hallmarks of IBD such as the ATF6 pathway as a
branch of the unfolded protein response (UPR), which were used
to identify novel anti-inflammatory ATF6 targeting compounds
(10). As organoids can provide experimental manipulability and
maintain at the same time biologic complexity, they function as a
bridge between conventional 2Dcell culture and animalmodels (2).A
B
C
FIGURE 1 | (A) Example of adult tissue-derived organoids (here: small intestine); IEC, intestinal epithelial cells; ISC, intestinal stem cell. (B) Overview of stem cell-
and (tumour) tissue-derived in vitro models (selection); iPSC, induced pluripotent stem cells. (C) Overview of co-culture systems (simplified selection): (1) apical-out
model of intestinal organoids for host-microbe-interaction studies, (2) 3D co-culture systems of immune cells with organoids, e.g., T cells/intestinal organoids and
microglia/brain organoids, (3) 2D co-culture systems with a polarized organoid monolayer with either immune cell (basal interface) or microbe (apical interface).December 2020 | Volume 11 | Article 573562
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pluripotent stem cell (iPSC)-derived organoid culture. Intestinal
organoids were one of the first iPSC-derived tissues consisting of a
polarised, columnar epithelium patterned into villus-like structures
and crypt-like proliferative zones (11). The iPSC technology has the
enormous potential to overcome the limitations of accessibility of
specific tissues, such as brain or heart, providing improved patient-
derived cellular models of human disease that can also be used for
drug screens and personalised treatment strategies (Figure 1B).
Cerebral brain organoids displayed various discrete though
interdependent brain regions (12). This potential is further
strengthened by combining iPSC technology with genome
engineering - allowing the correction of mutations in patient-
derived iPSCs (13) and the modification of reporter lines, thereby
facilitating differentiation towards specific cell types (14).
In the following, we will discuss the technical progress and
remaining limitations on using more complex cell culture models to
understand inflammatory disorders, host–pathogen interactions
or cancer.
PRECISE DISEASE MODELLING: CO-
CULTURES AND TISSUE ENGINEERING
TO STUDY AUTOIMMUNE DISEASES
AND INFECTIONS
A wide range of co-culture and organoid-based disease models that
reproduce genetic immune diseases (7, 8, 15) and host–pathogen
interactions (16, 17) have already been developed and provide proof
of principle that these complex cultures can showcertainwell-known
pathological features. These model systems are the result of
tremendous advances and bioengineering innovations of the
past decade.
Impaired epithelial host-microbe interaction is one of the
important features of IBD and thus, model systems focusing
on this interplay are needed (18). Due to the “apical-in/
basolateral-out” polarity of conventional organoid systems,
microbes need to be microinjected into the lumen of the
organoids to mimic physiological host-microbial cross-talks
(19–21). This technique however is slow, even with standardised
high-throughput approaches technically very challenging and the
reproducibility of the results is low due to the heterogeneity of the
organoids and their luminal content (22).
Tocombat this issueof “wrong”epithelialpolarity, an “apical-out”
system with reverse organoid polarity was developed (22) (Figure
1C), providing a more suitable and reliable model for processes and
properties of the epithelium, e.g. examining nutrient absorption and
host-pathogen interactions, such as inflammatory cytokines/
chemokines, antimicrobial peptides and ROS production.
Another approach to assess host-pathogen interactions is the co-
culturing of an epithelial monolayer of preserved apical-basolateral
polarity with selected pathogens (Figure 1C). Using such models, the
role of K. pneumoniae in priming TH17 response in primary
sclerosing cholangitis (15) or the pathophysiology of chronic
Helicobacter pylori infections (20, 23) were identified. Recently,
microfluidic-based systems, i.e. the human microbial crosstalkFrontiers in Immunology | www.frontiersin.org 3(HuMiX) system (24, 25), were established, enabling co-culturing
of human intestinal epithelial monolayers with anaerobic pathogens
and the analysis of diet-microbiome-human interactions. Besides
studies on antimicrobial response, the development of two-
dimensional organoid cultures with an air-liquid-interface
increased the complexity and maturation of the epithelial layer,
providing a better approximation to the in vivo tissue, similar to
colonic monolayers (26), and led to the discovery of a novel injury-
related cell type, associated with IBD-related tissue regeneration.
The interaction of the epithelium with the stroma, including
immune cells, mesenchymal cells and neuronal cells, is vital for
organ development and homeostasis and needs to be taken into
account when modelling complex immunological diseases like
IBD (27). Stromal cells provide the niche for stem cell growth by
production of ECM and secretion of essential growth factors,
such as WNT proteins (27) and R-spondin (28). Various in vitro
models (both 2D and 3D) have been co-cultured with different
types of immune cells to assess immune-related orchestration of
the epithelial barrier and vice versa the communication back to
the specialised immune cells (29). E.g., co-culturing of intestinal
organoids and macrophages led to enhanced barrier integrity
(30), and the epithelial-macrophage communication enabled a
more coordinated immune response to infection.
The enteric nervous system (ENS), controlling several
functions, such as motility and permeability, has been linked to
enteric neuropathies and gut disorders (31). To that end, a model
of co-culturing of intestinal epithelial cells with ENS neurons and
glia or subepithelial myofibroblasts was developed (32), showing
that the ENS influences intestinal stem cell (ISC) fate by increasing
differentiation towards the enteroendocrine lineage and thereby
modulates intestinal barrier function. Vice versa, immune cells like
tissue resident macrophages upon gastrointestinal infections
modulate cellular fate of enteric neurons (33). Going one step
further, human iPSC-derived intestinal tissue with a functional
ENS was generated by combining intestinal organoids with neural
crest cells, in order to investigate the pathophysiology of
Hirschsprung’s disease (31). This model could also provide a
platform for analysing the epithelium/ENS-axis in IBD.
Vice versa, environmental factors influencing the microbiome
(e.g. intestinal infections) are suggested to play a key role in the
initiation and progression of neurological disorders, such as
Parkinson’s disease (PD) (34–36). PD is characterised by the
loss of dopaminergic neurons and intracellular inclusions
composed mainly of alpha synuclein, which can be identified
in intestinal biopsies years prior to PD diagnosis (37). Notably, it
was shown that inflammatory processes, e.g. mitochondrial
stress-associated STING/IFN-I response in the absence of PD-
linked Parkin or Pink1 function, are drivers of PD pathology (36,
38). Therefore, it is of interest not only to examine disease
mechanisms of the gut-brain axis but also direct inflammatory
processes in the brain triggered by microglia activation (39). In
this regard, brain organoids in co-culture with microglia
represent a major breakthrough in neuronal disease modelling
techniques (40) and will serve to facilitate the development of
more precise human brain models for basic mechanistic studies
in neural-glial interactions and drug discovery.December 2020 | Volume 11 | Article 573562
Tran et al. Stem Cells and Organoid TechnologyThere remains one crucial factor none of these models accounts
for, that is blood vessels. Aside from transporting the vital contents
of our blood to and from the demanding organs, vascularization
is a critical component of physiological (and pathological)
development. Recently, human pluripotent stem cells were
engineered to induce endothelium development by expressing
ETS variant 2, which contributed to forming a complex vascular-
like network in human cortical organoids (41). Vascularized
organoids displayed enhanced functional maturation and
acquired several blood-brain barrier characteristics, including an
increase in the expression of tight junctions, nutrient transporters
and trans-endothelial electrical resistance. These cultures formed
vasculature-like structures that resemble the status in early prenatal
brain and present a robust model to study disease in vitro.
The key challenge of the next years will be the establishment of
multi-compartment in vitromodels for disease andbeyond the two-
compartment organoid co-culturing systems [e.g. organ/body-on-
a-chip, including tissue cultures from multiple organs (42, 43)], to
really represent complex, multi-organ immunological disorders.PATIENT IN A DISH: EXCURSUS ON
PREDICTING THERAPY RESPONSE IN
INFLAMMATION-DRIVEN CANCER
Inflammation is a driving aspect of oncogenesis and a necessary
component of the established tumour’s mechanism of resistance.
This aspect of the immune-oncological crosstalk has recently
gained attention due to the use of immunotherapy in nearly all
type of cancer (44). Previous oversimplified cell culturing
methods lack the tumour’s micro-environment, which have
only been partially resolved by co-culturing models of tumour
cell lines with other somatic cells (45–47) (Figure 2A). Animal
models, including genetic tumour models (GEM), murine-
derived organoids (MDO) and xenotransplants, display higher
degrees of tumour complexity, but are limited by inter-species
differences in immunological mechanisms and chemokine
signalling, compared to human cancer (48).
The possibility to easily generate primary tissue-derived
organoids provides the basis for personalised ex vivo models,
particularly in cancer research. Cancer-derived organoids
display several traits that are similar to the original tumour
and therefore allow the understanding of cancer biology by
large-scale tumour bio-banking and high-throughput drug
screenings, which gave rise to the discovery of novel anti-
tumour compounds (49).
The availability of CRISPR/Cas9 systems enabled genetic
engineering on (cancer) organoids with, however, highly variable
efficiency of genome editing, depending on the route of CRISPR-
Cas9 installation (50). As a proof of concept, sequential
introduction of hallmark colorectal cancer mutations into
human colonic organoids licenced growth factor independent
proliferation of the organoids and mimicked aspects of the
classical adenoma-carcinoma sequence (51). In the same study,
re-implantation of these transformed organoids in a murineFrontiers in Immunology | www.frontiersin.org 4metastasis model demonstrated that, beside canonical cancer
mutations, additional molecular lesions as chromosomal
instability are necessary for an invasive cancer behaviour.
Another example from the same group is the generation and
usage of CRISPR/Cas9-guided knock-in of LGR5- and KRT20-
reporters into cancer organoids to trace tumour stem cell
behaviour in vivo (52).
On an individualised level, patient cancer-derived organoids
(PDO) are suitable in the prediction of therapy response of an
individual tumour or metastases by high-throughput screenings
of therapies (e.g. compound screens, chemotherapy, irradiation)
on a small specimen in neo-adjuvant settings (53, 54).
To depict the complexity of tumour microenvironments,
including immuno-oncological cross-talks, distribution of
drugs and metabolites in the tumour etc., the need for cancer
organoid models exceeding the pure epithelial tissue was recently
defined (55). The following two strategies are pursued and
include the tumour epithelium and tumour-associated cell
types such as, immune cells or stroma:
i. The cultivation of organotypic tumour spheroids or tumour
cells on air-liquid interfaces is a more holistic approach and
mimics the complete tumour, however it requires a more
substantial (mostly surgical) specimen, which excludes the
use for neo-adjuvant strategies.
ii. Co-culture systems of PDO with separately sampled cells of
the microenvironment benefit from pre-established PDO
culture protocols. These models have the advantage that
specific cellular components of the microenvironment can
be addressed, and only small tumour specimens are necessary
for PDO generation.
Since the need for these complex PDO models and the
strategies to address the microenvironment are rather new,
there are some promising reports indicating that establishing
complex PDO models harbouring different cel lular
compartments are feasible and representative for the original
tumour (53, 56–59)
The advances of organoid research in both cancer and
inflammation (non-malignant) gave rise to potential model
systems, which, for instance, could depict the transition from
chronic inflammation to inflammatory-driven carcinogenesis.STANDARDISATION REMAINS THE
MAJOR CHALLENGE FOR IN VITRO
INFLAMMATION MODELS
As outlined, enormous advances in the stem cell and organoid
field have emerged and their potential in translational research,
and even healthcare, is obvious; however, current limitations of
organoids remain an important caveat (Figure 2B).
A general limitation of organoid derivation is the high
variability of the phenotypes that they can produce. Organoid
and stem cell culture systems and their molecular outcome are
critically dependent on the quality and properties of the sampledDecember 2020 | Volume 11 | Article 573562
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immune signatures of these samples. Moreover, inflamed tissue is
more likely to undergo cell death, might have different nutrient and
culturing needs and thus the recovery rate of vital organoids
from inflamed tissue is significantly lower (60). Whilst
inflammatory signatures ex vivo are similar to their in vivo origin
(9), particularly complex diseases such as IBD are characterised by
a diversity of inflammatory flavours. Furthermore, biopsies are
reflecting the biology of the sampled region, and therefore
stem cells/organoids should be harvested from different regions.
When using iPSCs, variations exist in organoids depending on
the genetic background of the individual and the culture
protocol used by the lab. Isogenic lines generated viaFrontiers in Immunology | www.frontiersin.org 5gene-editing approaches can limit this variability in regard to
genetic differences.
Because organoids from iPSCs are formed through
differentiation of a homogeneous population, tissue-specific cell
types and their microenvironment must be newly created. This
challenges the use of iPSCs and despite significant similarities in
structure and function between organoid and adult tissue, organoids
often retain immature characteristics, making them more similar to
foetal tissue. In an example of iPSC-derived intestinal organoid, this
limitation could be resolved by either co-culturing it with T cells
providing a more realistic growth niche (61), engineering of more
sophisticated 3D scaffolds to improve organoid architecture and
thus increase the similarity to the original tissue in vivo (62, 63), orA
B
FIGURE 2 | (A) Properties of the discussed models for translational research; GEM, genetically engineered mouse model; MDO, murine-derived organoid; iPS,
induced pluripotential stem cell; PDO, patient-derived organoid; definition of colours: Green - possible/cheap (costs)/easy (success rate)/1–2 weeks (time); Yellow:
medium (costs)/medium (success rate)/1–2 months (time); orange – 1–6 months (time); red - difficult/expansive (costs)/low (success rate)/over 6 months (time).
(B) Overview over the proposed challenges in the standardisation of organoid culturing systems.December 2020 | Volume 11 | Article 573562
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epithelium with preserved intestinal stem cell niches, crypt/villus
architecture and a laminated human mesenchyme, both supported
by mouse vascular ingrowth (64). Apart from immature
characteristics, organoids often show a limited lifespan once a
certain size is reached. Due to the lack of diffusion, cells are not
supplied with sufficient nutrients to support continued
development. The use of bioreactors could improve the nutrient
supply. Ideally, organoids are engineered towards the induction of
endothelium development resulting in vascularization as shown
recently (41). Another strategy would be to integrate endothelial
cells, or their progenitors, during organoid development, and to
include bioprinting methods to design 3D-scaffolds for the
endothelial cells (65, 66). However, the original material tissue of
iPSC-derived organoids is usually not inflamed, e.g. skin fibroblasts,
and have been reprogrammed and cultured for many weeks to
months in the absence of an inflammatory milieu. For the study of
complex, multifactorial inflammation, iPSC-derived systems are
therefore not the first choice in terms of a model. Vice versa,
iPSC-derived organoids might be excellent tools to study mainly
genetically driven inflammatory disorders, such as monogenic IBD.
Another important challenge is the magnitude of effort, time and
expenses spent on organoid cultures. Whilst rather simple protocols
are available for conventional organoid cultures at manageable costs,
differentiation protocols include either expensive factors or culturing
media or require conditioned media, which need to be produced by
feeder cell lines. Co-culturing systems often include 2Dmodels, which
require much higher culturing efforts and time. Adding to this
challenge, the generation of iPSC and their differentiation into
specific tissue often require several weeks of intense culturing effort,
which increases the risk of adverse events, e.g. contamination or
undesired differentiation.
To combat the aforementioned issues, close collaboration of
academic research and high-tech industrial partners may be a
promising strategy to overcome the infrastructural challenges.
Whilst academia can provide problem-derived ideas and a
hypothesis-driven vision of novel disease models, industry can
deliver the necessary technology, capacities for large-scale
production and standardisation. Setting up these collaborative
infrastructures are necessary and can foster future advances of
stem cell technology.CONCLUSIONS AND FUTURE
PERSPECTIVES
Organoids have been shown to keep key multicellular, anatomical
and to some degree even functional hallmarks of real organs. In
order to exploit these improved disease models, the application of
high-throughput analysis techniques and large-scale perturbation
tools to organoids is required. Single-cell multi-omics (19, 20) and
imaging technologies can provide insight into underlying
pathological mechanisms at different regulatory molecular layers.
Physiological interactions of different organs could be modelled by
using microfluidics and organ-on-a-chip technologies to study key
systemic interactions in diseases. The combination of advancedFrontiers in Immunology | www.frontiersin.org 6organoid models and these techniques might even enable to
understand the early molecular mechanisms that cause cells to
deviate from a healthy to a disease trajectory (67). This might lead
to the detection of biomarkers for the prodromal disease state and
the identification of new drug targets to intercept diseases before
manifestation of symptoms.
One of the visions of stem cell research is the development of
stem-cell-derived regenerative tissue for engraftment and
transplantation purposes. Recently, a group successfully
engrafted human iPSC-derived kidney organoids into
immunodeficient NOD/SCID mice, which reached a higher
degree of maturation compared to in vitro kidney organoids but
still markedly immature compared to the neighbouring mouse
kidney tissue (68). Besides tissue repair, this technology can be a
promising vehicle for targeted gene therapy, especially for
monogenic disorders. The advances in CRISPR/Cas9 technology
already allow selective genome editing with a reduced number of
off-target effects by using engineered secondary RNA structures
(69) or by implementing prime editing guide RNA that specifies
the target site and encodes the desired edit (70). However, only
complete and definite exclusion of any off-target DNA alterations
are acceptable for transplantation purposes.
It will be of great importance to implement organoids as a
platform for screening and testing personalised medicine
treatments, as they are cultures of primary patient material.
Whilst this is already possible for cancer (54), it will in the future
also be possible for inflammatory disorders that affect epithelial
tissues. We expect implementation of these systems in drug
discovery, therapy guidance and tissue regenerative medicine.
Therefore, joint efforts of academia and industrial partners are
mandatory to surpass challenges in regard to safety and reliability.AUTHOR CONTRIBUTIONS
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